Idiopathic Anaphylaxis - What to do when a cause eludes you

Price: FREE for members and non-members
Session recorded on February 18, 2020
Speaker: Anne Ellis, MD
Viewers can earn credit by completing the post test questions.

This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.

There is no commercial support for this activity.

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Practicing allergists/immunologists

Learning Objectives

Upon completion of this video recording, participant should be able to:
1.    Describe the essential pathophysiologic mechanisms of anaphylaxis
2.    Diagnose idiopathic anaphylaxis accurately
3.    Discuss appropriate work up strategies for anaphylaxis when cause is not obvious

Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a "commercial interest" as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.



Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
Course expires: 

All identified conflicts of interest have been resolved.

Sally Schlosser, RN, Planner, Reviewer
Nothing to disclose

Michael Blaiss, MD, Planner
Disclosures: Consultant/Consulting fee: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare

Anne Ellis, MD, Speaker
Disclosures: Grants to Institution: Bayer LLC, Circassia Ltd., Green Cross Pharmaceuticals, GlaxoSmithKline, Sun Pharma, Marck, Novartis, Pfizer, Regeneron and Sanofi, Advisory Boards: ALK Abello, AstraZeneca, Aralez, Bausch Health, Circassia Ltd., GlaxoSmithKline, Johnson & Johnson, Merck, Mylan, Novartis, Pediapharm and Pfizer
Speaker: ALK, Aralez, AstraZeneca, Boerhinger-Ingelheim, CACME, Meda, Mylan, Merck, Novartis, Pediapharm, Pfizer, The ACADMEY, and Takeda
Other: Independent consultant to Allergy Therapeutics, Bayer LLC, Ora Inc. and Regeneron in the past.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.